Matthew Bright and Shannon Hayne have no competing interests. The use of ultrasonic cavitation to obtain SVF from adipose is a filed Patent Co-operation (PCT) patent by Cell-Innovations. The use of SVF and stem cells for the use of migraines and TTH are filed PCT patents. Ralph Bright and Wayne Thomas are Directors of Cell-Innovations. Pelin Bright is a shareholder of Cell-Innovations.
MB, RB, PB and WT performed the procedures, collected the patient data, and assisted with completion of the manuscript. SH was a major contributor in writing the manuscript. All authors read and approved the final manuscript.
Chronic migraines and tension-type headaches are debilitating diseases affecting 1.4 to 2.2% of the population with both quality of life and economic implications. To date, the pain associated with migraine and tension-type headaches has been controlled with a range of medications, with varying levels of success. In addition, the side-effect profile of these medications, as well as their potential for addiction, has been a cause for concern for both patients and physicians.
Four women with long histories of migraine or frequent tension-type headache that meet the International Classification of Headache Disorders criteria for Chronic Migraine or Tension-type Headaches were given a systemic treatment(s) of autologous stromal vascular fraction or autologous ‘StroMed’ isolated from lipoaspirate. StroMed is stromal vascular fraction cells prepared by ultrasonic cavitation. Two of the four patients, both of whom are Arab women aged 40 and 36 years, ceased having migraines after 1 month, for a period of 12 to 18 months. The third patient, a Slavic woman aged 43 years, had a significant decrease in the frequency and severity of migraines with only seven migraines over 18 months. The fourth patient, an Asian woman aged 44 years, obtained a temporary decrease for a period of a month and was retreated 18 months later and has been free of migraines to date for 1 month. Pain medication was typically reduced from prescribed opioid analgesia to non-steroidal anti-inflammatory drugs and paracetamol.
This case series is the first to provide evidence of the efficacy of autologous StroMed and stromal vascular fraction in the treatment of migraine and tension-type headache. The treatment of this disease by stromal vascular fraction adds a new dimension to its clinical applicability and suggests a relatively simple treatment that may help address the symptoms of the disease. Given what is known about the components of the stromal vascular fraction and how they act, the information presented in this case series may also further our knowledge of the etiology and pathophysiology of migraine and tension-type headaches. This treatment is simple, looks to be extremely effective and has been life changing for these patients.
Reynolds SD, Giangreco A, Hong KU, McGrath KE, Ortiz LA, Stripp BR: Airway injury in lung disease pathophysiology: selective depletion of airway stem and progenitor cell pools potentiates lung inflammation and alveolar dysfunction. Am J Physiol Lung Cell Mol Physiol. 2004, 287: L1256-L1265. 10.1152/ajplung.00203.2004. CrossRefPubMed
- Migraine and tension-type headache treated with stromal vascular fraction: a case series
Wayne D Thomas
- BioMed Central